AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24716651 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 20
Study 23419888 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led groups
Number of subjects: 319
Study 23419888 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-led groups
Number of subjects: 319
Study 23419888 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 319
Study 23419888 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure control
Number of subjects: 319
Study 20627032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 5 mg/d
Number of subjects: 42
Study 20627032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg/d
Number of subjects: 42
Study 20627032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 20 mg/d
Number of subjects: 42
Study 20627032 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg/d
Number of subjects: 42
Study 18256346 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (n = 20)
Number of subjects: 60
Study 18256346 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (n = 20)
Number of subjects: 60
Study 18256346 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 60
Study 16606388 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-fixation leads (1488T St. Jude and Medtronic 5076)
Number of subjects: 100
Study 12742556 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/desogestrel
Number of subjects: 47
Study 12742556 — intervention group
Group type: COMPARATOR
Intervention: ethinyl estradiol/levonorgestrel
Number of subjects: 47
Study 10389774 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg of epinephrine IV
Number of subjects: 96
Study 10389774 — intervention group
Group type: COMPARATOR
Intervention: 3 mL of saline IV
Number of subjects: 96
Study 9015519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin, 400 micrograms/kg, 12 fortnightly doses
Number of subjects: 37
Study 9015519 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC), 10 mg/kg, 12 fortnightly doses
Number of subjects: 37
Study 9015519 — intervention group
Group type: COMPARATOR
Intervention: Low dose ivermectin (LDIC group)
Number of subjects: 37
Study 2006699 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 50
Study 2006699 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 50
Study 2006699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7039813 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD (thioguanine + Ara‐C + Daunorubin)
Number of subjects: 455
Study 7039813 — intervention group
Group type: EXPERIMENTAL
Intervention: DA (Daunorubicin + Ara‐C)
Number of subjects: 455
Study 7039813 — intervention group
Group type: EXPERIMENTAL
Intervention: AVML (Arabinosyl Cytosine + vincristine + methotrexate + leucovorin)
Number of subjects: 455
Study 7039813 — intervention group
Group type: COMPARATOR
Intervention: DA vs TAD
Number of subjects: 455
Study 7039813 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy (B/A, BCG, NFT)
Number of subjects: 455
Study 7039813 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (Bacillus Calmette‐Guerin)
Number of subjects: 455
Study 3902388 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (32 mg once daily)
Number of subjects: 13
Study 3902388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3902388 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 13
Study 28932882 — intervention group
Group type: EXPERIMENTAL
Intervention: No episiotomy
Number of subjects: 309
Study 28932882 — intervention group
Group type: COMPARATOR
Intervention: Standard care (episiotomy)
Number of subjects: 309
Study 25803759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar transforaminal epidural injection
Number of subjects: 80
Study 25803759 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-controlled lumbar transforaminal epidural injection
Number of subjects: 80
Study 24782192 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profiles in peripheral whole blood samples
Number of subjects: 0
Study 22369601 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fetal movement counting from pregnancy week 28
Number of subjects: 1013
Study 22369601 — intervention group
Group type: COMPARATOR
Intervention: Standard Norwegian antenatal care (control)
Number of subjects: 1013
Study 22369601 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fetal movement counting
Number of subjects: 1013
Study 20660830 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan plus Cyclophosphamide (TOPO/CTX)
Number of subjects: 119
Study 20660830 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (TOPO)
Number of subjects: 119
Study 20660830 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (TOPO) and Topotecan plus Cyclophosphamide (TOPO/CTX)
Number of subjects: 119
Study 18413423 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-release ENG implant combined with TU injections (750 mg every 10 or 12 weeks)
Number of subjects: 354
Study 18413423 — intervention group
Group type: EXPERIMENTAL
Intervention: High-release ENG implant combined with TU injections (1000 mg every 12 weeks)
Number of subjects: 354
Study 18413423 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment groups (ENG implant with TU injections)
Number of subjects: 354
Study 18413423 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment groups
Number of subjects: 354
Study 18413423 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 354
Study 15854634 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilostane (120 mg twice daily for the first 24 h, then 240 mg twice daily for the next 24 h) + misoprostol (low-dose vaginal group: 200 microg every 4 h)
Number of subjects: 93
Study 15854634 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilostane + misoprostol (high-dose vaginal group: initial dose of 400 microg followed by 200 microg every 4 h)
Number of subjects: 93
Study 15854634 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilostane + misoprostol (vaginal-oral group: 400 microg vaginally followed by 200 microg orally every 4 h)
Number of subjects: 93
Study 12439845 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (recombinant human erythropoietin)
Number of subjects: 10
Study 10529135 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS)
Number of subjects: 107
Study 10529135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 7591314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital treatment with anistreplase followed by placebo after hospital admission (pre-hospital group; 2750 patients)
Number of subjects: 5469
Study 7591314 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by anistreplase (hospital group; 2719 patients)
Number of subjects: 5469
Study 2144914 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable resistance dynamic exercise every other week (1X/2 weeks, n = 19)
Number of subjects: 114
Study 2144914 — intervention group
Group type: EXPERIMENTAL
Intervention: Once per week (1X/week, n = 22)
Number of subjects: 114
Study 2144914 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice per week (2X/week, n = 23)
Number of subjects: 114
Study 2144914 — intervention group
Group type: EXPERIMENTAL
Intervention: Three times per week (3X/week, n = 21)
Number of subjects: 114
Study 2144914 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training once per week (n = 14)
Number of subjects: 114
Study 2144914 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training, n = 15)
Number of subjects: 114
Study 7031861 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg bacampicillin 3 times daily
Number of subjects: 47
Study 7031861 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg bacampicillin twice daily
Number of subjects: 47
Study 7031861 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg bacampicillin
Number of subjects: 47
Study 7031861 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg bacampicillin
Number of subjects: 47
Study 31256644 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drain (CSD)
Number of subjects: 29
Study 31256644 — intervention group
Group type: COMPARATOR
Intervention: Sham drain (SCDRN)
Number of subjects: 29
Study 29787357 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 175
Study 29787357 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 175
Study 26903039 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 2559
Study 25122976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating power toothbrush with angled CrissCross bristles
Number of subjects: 130
Study 25122976 — intervention group
Group type: COMPARATOR
Intervention: Sonic toothbrush (Sonicare DiamondClean)
Number of subjects: 130
Study 22976566 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ozonated olive oil (OZO) as an adjunct to scaling and root planing (SRP)
Number of subjects: 20
Study 22976566 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ozonated olive oil (OZO) as a monotherapy
Number of subjects: 20
Study 22976566 — intervention group
Group type: COMPARATOR
Intervention: Topical chlorhexidine gel as a monotherapy
Number of subjects: 20
Study 22976566 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 20
Study 20860635 — intervention group
Group type: EXPERIMENTAL
Intervention: Askina Calgitrol Ag(®)
Number of subjects: 65
Study 20860635 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine (1% AgSD)
Number of subjects: 65
Study 17990196 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR treatment (eight weekly sessions)
Number of subjects: 33
Study 17990196 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 33
Study 17990196 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR treatment
Number of subjects: 33
Study 15898028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (7.5 microg)
Number of subjects: 40
Study 15898028 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sufentanil (7.5 microg)
Number of subjects: 40
Study 11127247 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis for > or = 8 weeks
Number of subjects: 0
Study 11127247 — intervention group
Group type: COMPARATOR
Intervention: Case management
Number of subjects: 0
Study 11127247 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron‐folic acid supplementation
Number of subjects: 0
Study 11127247 — intervention group
Group type: COMPARATOR
Intervention: Case management with parasitaemia and haemoglobin levels < 100 g/L
Number of subjects: 0
Study 11127247 — intervention group
Group type: COMPARATOR
Intervention: Case management with low haemoglobin level at enrolment
Number of subjects: 0
Study 11127247 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis
Number of subjects: 0
Study 9417816 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TNF, interferon gamma, and melphalan (TIM) in isolated limb perfusion (ILP)
Number of subjects: 44
Study 9417816 — intervention group
Group type: COMPARATOR
Intervention: ILP without TNF/interferon gamma (IFN-gamma)
Number of subjects: 44
Study 9417816 — intervention group
Group type: EXPERIMENTAL
Intervention: TIM-ILP
Number of subjects: 44
Study 9417816 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNF-RII concentration in excess over circulating TNF
Number of subjects: 44
Study 8317533 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo transfer, zygote intrafallopian transfer, and frozen embryo transfer
Number of subjects: 45
Study 2872822 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine (7-day course)
Number of subjects: 39
Study 2872822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7-day course)
Number of subjects: 39
Study 30045168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with CDI
Number of subjects: 12274
Study 30045168 — intervention group
Group type: COMPARATOR
Intervention: Non-cirrhosis patients with CDI
Number of subjects: 12274
Study 30045168 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompensated cirrhosis patients
Number of subjects: 12274
Study 28207505 — intervention group
Group type: EXPERIMENTAL
Intervention: EBCA (esomeprazole and colloidal bismuth pectin with clarithromycin and amoxicillin)
Number of subjects: 270
Study 28207505 — intervention group
Group type: EXPERIMENTAL
Intervention: EBLA (esomeprazole and colloidal bismuth pectin with levofloxacin and amoxicillin)
Number of subjects: 270
Study 28207505 — intervention group
Group type: EXPERIMENTAL
Intervention: ELA (esomeprazole with levofloxacin and amoxicillin)
Number of subjects: 270
Study 26025562 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 15 mg with melatonin-SR 3 mg
Number of subjects: 0
Study 26025562 — intervention group
Group type: COMPARATOR
Intervention: Buspirone 15 mg
Number of subjects: 0
Study 26025562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22959634 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 8
Study 22959634 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study 21996389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine-treated graft
Number of subjects: 93
Study 19220284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 40
Study 17028221 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine dilution (1:1 or 1:10)
Number of subjects: 0
Study 17028221 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous vaccinia virus vaccination status
Number of subjects: 0
Study 15871456 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-face stainless steel crowns (SSCs)
Number of subjects: 33
Study 15871456 — intervention group
Group type: COMPARATOR
Intervention: Veneered stainless steel crowns (SSCs)
Number of subjects: 33
Study 10721538 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (specifically amoxycillin as first line treatment)
Number of subjects: 0
Study 10721538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9305231 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 micrograms once daily
Number of subjects: 550
Study 9305231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms once daily
Number of subjects: 550
Study 9305231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 8360362 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridol mouthrinse
Number of subjects: 36
Study 8360362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 36
Study 8360362 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 36
Study 3540309 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral stress management
Number of subjects: 10
Study 3540309 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 10
Study 30003808 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal website
Number of subjects: 116
Study 30003808 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Media Index (SMI) above 3
Number of subjects: 116
Study 30203534 — intervention group
Group type: EXPERIMENTAL
Intervention: Prabotulinumtoxin A (NABOTA®)
Number of subjects: 22
Study 30203534 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A (ONA)
Number of subjects: 22
Study 30203534 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 29173604 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst exercise (3 continuous bursts of 12 minutes of high-intensity exercise at 85% of maximal heart rate, 5 days per week for 3 months)
Number of subjects: 40
Study 29173604 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst exercise
Number of subjects: 40
Study 29173604 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise training (MICT) (40 minutes at 60% of maximal heart rate, 5 days per week for 3 months)
Number of subjects: 40
Study 26361154 — intervention group
Group type: EXPERIMENTAL
Intervention: Top tertiles of Lp(a)
Number of subjects: 220
Study 26361154 — intervention group
Group type: EXPERIMENTAL
Intervention: Top tertiles of OxPL-apoB
Number of subjects: 220
Study 26361154 — intervention group
Group type: EXPERIMENTAL
Intervention: Top tertiles of Lp(a) or OxPL-apoB after adjustment
Number of subjects: 220
Study 24139769 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshplace intervention
Number of subjects: 228
Study 24139769 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional food pantries)
Number of subjects: 228
Study 20841314 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) (Transbond Plus)
Number of subjects: 80
Study 20841314 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid (PA) (37% for 30 seconds)
Number of subjects: 80
Study 20841314 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP)
Number of subjects: 80
Study 18356656 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of dexamethasone
Number of subjects: 28
Study 18356656 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (control)
Number of subjects: 28
Study 16554592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal brachytherapy using iridium-192 with a dose of 14 Gy
Number of subjects: 40
Study 16554592 — intervention group
Group type: COMPARATOR
Intervention: Control group with a dummy source
Number of subjects: 40
Study 14567808 — intervention group
Group type: EXPERIMENTAL
Intervention: SprayGel
Number of subjects: 45
Study 14567808 — intervention group
Group type: COMPARATOR
Intervention: Control (no SprayGel)
Number of subjects: 45
Study 10730995 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 2.5 ATA for 60 min
Number of subjects: 24
Study 10730995 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with normoxic mixture (P(I)O2 = 0.2 ATA)
Number of subjects: 24
Study 10730995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HBOT and placebo)
Number of subjects: 24
Study 8040015 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy covering the whole sphenoid sinus
Number of subjects: 152
Study 8040015 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy using a modified technique that shields the pituitary and the anterior part of the hypothalamus
Number of subjects: 152
Study 8040015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 152
Study 3057146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 58
Study 3057146 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 58
Study 3057146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 31394300 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive photodynamic therapy (PDT) with full-mouth disinfection (FMD)
Number of subjects: 30
Study 31394300 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth disinfection (FMD) alone
Number of subjects: 30
Study 28486704 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention programme preceding infertility treatment
Number of subjects: 564
Study 28486704 — intervention group
Group type: COMPARATOR
Intervention: Prompt infertility treatment
Number of subjects: 564
Study 28486704 — intervention group
Group type: EXPERIMENTAL
Intervention: All live births conceived within 24 months
Number of subjects: 564
Study 25853229 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly motivational counseling
Number of subjects: 57
Study 25853229 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study 23169517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg daily)
Number of subjects: 171
Study 23169517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 171
Study 23169517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 21336155 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.004% once daily
Number of subjects: 30
Study 21336155 — intervention group
Group type: COMPARATOR
Intervention: pilocarpine 1% 4 times daily
Number of subjects: 30
Study 21336155 — intervention group
Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 30
Study 19171726 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (gastric banding surgery)
Number of subjects: 0
Study 19171726 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 17521747 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal bovie tonsillectomy
Number of subjects: 39
Study 17521747 — intervention group
Group type: COMPARATOR
Intervention: Total monopolar tonsillectomy
Number of subjects: 39
Study 15064584 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine-arginine-alpha-ketoisocaproic acid (GAKIC) 11.2 g
Number of subjects: 10
Study 15064584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 10
Study 15064584 — intervention group
Group type: EXPERIMENTAL
Intervention: GAKIC
Number of subjects: 10
Study 15064584 — intervention group
Group type: COMPARATOR
Intervention: GAKIC and PLC
Number of subjects: 10
Study 11685491 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy radioiodine dose
Number of subjects: 58
Study 11685491 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 Gy radioiodine dose
Number of subjects: 58
Study 11685491 — intervention group
Group type: COMPARATOR
Intervention: Low-dose therapy (60 Gy)
Number of subjects: 58
Study 11685491 — intervention group
Group type: COMPARATOR
Intervention: Low-dose therapy (90 Gy)
Number of subjects: 58
Study 9555775 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz‐Schatz coronary stent
Number of subjects: 407
Study 9555775 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 407